ALSO NOTED: Pfizer demands peer reviews from NEJM; Novartis gets EU nod for diabetes combo;

> Pfizer wants the New England Journal of Medicine to turn over confidential peer reviews of studies involving the painkillers Celebrex and Bextra; those articles have been cited in plaintiffs' lawsuits over the drugs. Report

> Novartis won the nod from European regulators for its diabetes combo treatment Eucreas, which comprises the company's new Galvus treatment and old standby metformin. Report

> President Bush's new FDA budget includes a boost in funding for examination of DTC ads; the catch is that the funding comes from user fees, a method Congress rejected last year. Report

> FTC Commissioner Jon Leibowitz explained his agency's opposition to pay-to-delay deals between brand-name drug makers and generics firms in a Washington Post op-ed piece. Report

> Boston Scientific got the FDA nod for three heart-related products: Confient and Livian, two defibrillators; and Latitude, a computer system that helps doctors monitor patients' hearts between visits. Report

> The FDA has granted priority review to Eli Lilly and Daiichi Sankyo's prasugrel, an anti-clotting drug. Report

> Novartis has established the Novartis Vaccines Institute for Global Health, a nonprofit venture that will take aim at diseases in the developing world. Report

And Finally... The shooting spree at Northern Illinois University has revived a debate over antidepressants and whether they might be linked to violent behavior. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.